PBAC's latest decision on Pneumococcal conjugate vaccine, 15-valent: Recommended with restriction (2023). Considered for Active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F) in infants, children and adolescents up to 18 years of age, including non-Indigenous and Aboriginal and Torres Strait Islander populations, those with specified medical risk conditions, and haematopoietic stem cell transplant recipients.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Paediatric populations aged 6 weeks to <18 years: non-Indigenous infants and Aboriginal and Torres Strait Islander infants in ACT, NSW, Vic and Tas receiving 2+1 doses; infants with specified medical risk conditions and Aboriginal and Torres Strait Islander infants in WA, NT, SA and Qld receiving 3+1 doses; children and adolescents 12 months to 18 years newly diagnosed with specified medical risk conditions receiving 1 dose; and haematopoietic stem cell transplant recipients aged 12 months to <18 years receiving 3 doses.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Immunogenicity (serotype-specific IgG responses)
Pivotal trial size
6,608 patients
Key trials
P025, P026, P029, P031, P023, P030, P024, P027
Comparator
13-valent pneumococcal conjugate vaccine (13vPCV)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as the submission assessed 15vPCV as equi-effective to 13vPCV.